Chronic Obstructive Pulmonary Disease (COPD) and Osteoporosis

Patho-physiology of Osteoporosis in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01067248

Enrollment

120

Registered

2010-02-11

Start date

2010-01-31

Completion date

2012-12-31

Last updated

2015-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis, Pulmonary Disease, Chronic Obstructive

Keywords

COPD, Osteoporosis, Pathophysiology, Mechanism, Bone markers, Bone turnover, Protein turnover, Ageing, Endocrinology, Vitamin D

Brief summary

The main objective is to study important factors in the patho-physiology of osteoporosis in patients with COPD. Therefore, the investigators will study biological markers in plasma and urine and correlate them to markers of bone turnover and clinical data.

Detailed description

Rationale: Chronic obstructive pulmonary disease (COPD) is defined as a preventable and treatable disease with significant extrapulmonary effects. Osteoporosis is recognized as one of these extrapulmonary consequences. It results in increased risk of fracture and thereby an increased morbidity and mortality. Nowadays it is believed that the patho-physiology of osteoporosis is multi-factorial. However, which factors are most important in patients with COPD is still not clear. Objective: The main objective is to study important factors in the patho-physiology of osteoporosis in patients with COPD. Therefore, we will study biological markers in plasma and urine and correlate them to markers of bone turnover and clinical data. Study design: The present study will be an observational, cross-sectional study.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

for the COPD patients: * Aged 50 years or older; * Women have to be postmenopausal (amenorrhea for 12 months or more) * COPD Global initiative of Obstructive Lung Disease (GOLD) I, II, III and IV according to the American Thoracic Society (ATS) guidelines; * ≥ 12 pack years; * No respiratory tract infection or exacerbation of the disease for at least 4 weeks before the study; * No use of oral corticosteroids for at least 4 weeks before the study; * No use of anti-osteoporotic medication (calcium, vitamin D, biphosphonates) before inclusion; * Capable to provide informed consent.

Exclusion criteria

for the COPD patients: * Malignancy in the last 5 years; * Lung fibrosis; * Inflammatory bowel disease; * Rheumatoid arthritis; * Alcohol abuse; * Bronchiectasia; * Auto immune diseases; * Hypothyroidism or hyperthyroidism based on blood sampling for thyroid hormone (TSH, fT4).

Outcome results